To exploit the unique pattern of TRAIL-R2 expression, we developed a bsAb able to simultaneously bind TRAIL-R2 in an agonistic manner on cancer cells and the CD3-triggering molecule on T lymphocytes and demonstrated that this reagent could efficiently redirect their cytotoxicity against tumor cells in vitro. Here, TNFRSF10B is linked to neoplasm.